Medivation's Xtandi Fares Better Than Casodex In Prostate Cancer Trial
April 02, 2015 at 15:57 PM EDT
Shares of Medivation are up about 3% in the trading session after news that Xtandi showed better efficacy than Casodex in a Prostate Cancer clinical trial.
